Improved survival with MEK inhibition in BRAF-mutated melanoma.

doi:10.1056/NEJMoa1203421

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Improved survival with MEK inhibition in BRAF-mutated melanoma.

The New England journal of medicine - 12 Jul 2012

Flaherty Keith T, Robert Caroline, Hersey Peter, Nathan Paul, Garbe Claus, Milhem Mohammed, Demidov Lev V, Hassel Jessica C, Rutkowski Piotr, Mohr Peter, Dummer Reinhard, Trefzer Uwe, Larkin James M G, Utikal Jochen, Dreno Brigitte, Nyakas Marta, Middleton Mark R, Becker Jürgen C, Casey Michelle, Sherman Laurie J, Wu Frank S, Ouellet Daniele, Martin Anne-Marie, Patel Kiran, Schadendorf Dirk

Abstract excerpt

BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population. METHODS: In this phase 3 open-label trial, we randomly assigned 322 patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed

Identifiers

PMID: 22663011
DOI: 10.1056/NEJMoa1203421

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved survival with MEK inhibition in BRAF-mutated melanoma.PMID 22663011Read ↗

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Semantic proximity Read ↗

Targeted Therapy for Melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.